{
    "nct_id": "NCT05854498",
    "official_title": "Phase II Study of Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer",
    "inclusion_criteria": "* Patients must be â‰¥ 18 years of age\n* Eastern Cooperative Oncology Group (ECOG) performance must be 0 or 1.\n* Patients must have a histologically or cytologically confirmed diagnosis of colorectal adenocarcinoma and be metastatic or unresectable.\n* The cancer must be mismatch repair proficient.\n* Patients must have had prior treatment with 5-fluorouracil, oxaliplatin, irinotecan containing regimens. If RAS wild-type must have received prior anti-EGFR therapy with either cetuximab or panitumumab. If RAS wild-type and HER2 positive then must have had a prior HER2 targeted therapy.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Uncontrolled concurrent medical illness that would not allow for the completion of the planned therapy.\n* Patients whose cancers possess BRAF V600 mutations are excluded.\n* Patients must stop the use of strong inducers/inhibitors of CYP3A4 at least 2 weeks before initiating therapy.\n* Patients must not have mismatch repair deficient or microsatellite instability high cancers.\n* Patients must not have received prior TAS102.",
    "miscellaneous_criteria": ""
}